Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. 2007

Limei Yin, and Ken-Ichirou Morishige, and Toshifumi Takahashi, and Kae Hashimoto, and Seiji Ogata, and Seiji Tsutsumi, and Keiko Takata, and Tsuyoshi Ohta, and Jun Kawagoe, and Kazuhiro Takahashi, and Hirohisa Kurachi
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan.

Vascular endothelial growth factor (VEGF)-induced endothelial cell migration is an important component of tumor angiogenesis. Rho and Rho-associated kinase (ROCK) are key regulators of focal adhesion, stress fiber formation, and thus cell motility. Inhibitors of this pathway have been shown to inhibit endothelial cell motility and angiogenesis. In this study, we investigated the antiangiogenic effect of fasudil, one of the ROCK inhibitors. Fasudil inhibited VEGF-induced endothelial cell migration, viability, and tube formation in vitro in human umbilical vein endothelial cells. VEGF-induced endothelial cell migration was reduced by fasudil associated with loss of stress fiber formation, focal adhesion assembly, and with the suppression of tyrosine phosphorylation of focal adhesion proteins. Furthermore, fasudil inhibited VEGF-induced phosphorylation of myosin light chain, which is one of the main substrates of ROCK. Therefore, the effect of fasudil was suggested to be ROCK dependent. Fasudil not only inhibited VEGF-induced cell proliferation but also reversed the protective effect of VEGF on apoptosis, which resulted in the decrease of cell viability. Moreover, fasudil inhibited VEGF-induced angiogenesis in a directed in vivo angiogenesis assay. These data are the first demonstration that fasudil has antiangiogenic properties. Therefore, fasudil might be useful for the treatment of angiogenesis-related diseases, especially cancer.

UI MeSH Term Description Entries
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014471 Umbilical Veins Venous vessels in the umbilical cord. They carry oxygenated, nutrient-rich blood from the mother to the FETUS via the PLACENTA. In humans, there is normally one umbilical vein. Umbilical Vein,Vein, Umbilical,Veins, Umbilical
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D017346 Protein Serine-Threonine Kinases A group of enzymes that catalyzes the phosphorylation of serine or threonine residues in proteins, with ATP or other nucleotides as phosphate donors. Protein-Serine-Threonine Kinases,Serine-Threonine Protein Kinase,Serine-Threonine Protein Kinases,Protein-Serine Kinase,Protein-Serine-Threonine Kinase,Protein-Threonine Kinase,Serine Kinase,Serine-Threonine Kinase,Serine-Threonine Kinases,Threonine Kinase,Kinase, Protein-Serine,Kinase, Protein-Serine-Threonine,Kinase, Protein-Threonine,Kinase, Serine-Threonine,Kinases, Protein Serine-Threonine,Kinases, Protein-Serine-Threonine,Kinases, Serine-Threonine,Protein Kinase, Serine-Threonine,Protein Kinases, Serine-Threonine,Protein Serine Kinase,Protein Serine Threonine Kinase,Protein Serine Threonine Kinases,Protein Threonine Kinase,Serine Threonine Kinase,Serine Threonine Kinases,Serine Threonine Protein Kinase,Serine Threonine Protein Kinases
D042461 Vascular Endothelial Growth Factor A The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced. Vascular Endothelial Growth Factor,Vascular Endothelial Growth Factor-A,GD-VEGF,Glioma-Derived Vascular Endothelial Cell Growth Factor,VEGF,VEGF-A,Vascular Permeability Factor,Vasculotropin,Glioma Derived Vascular Endothelial Cell Growth Factor,Permeability Factor, Vascular

Related Publications

Limei Yin, and Ken-Ichirou Morishige, and Toshifumi Takahashi, and Kae Hashimoto, and Seiji Ogata, and Seiji Tsutsumi, and Keiko Takata, and Tsuyoshi Ohta, and Jun Kawagoe, and Kazuhiro Takahashi, and Hirohisa Kurachi
March 2001, The American journal of pathology,
Limei Yin, and Ken-Ichirou Morishige, and Toshifumi Takahashi, and Kae Hashimoto, and Seiji Ogata, and Seiji Tsutsumi, and Keiko Takata, and Tsuyoshi Ohta, and Jun Kawagoe, and Kazuhiro Takahashi, and Hirohisa Kurachi
January 2015, Ophthalmic research,
Limei Yin, and Ken-Ichirou Morishige, and Toshifumi Takahashi, and Kae Hashimoto, and Seiji Ogata, and Seiji Tsutsumi, and Keiko Takata, and Tsuyoshi Ohta, and Jun Kawagoe, and Kazuhiro Takahashi, and Hirohisa Kurachi
December 2020, Journal of anesthesia,
Limei Yin, and Ken-Ichirou Morishige, and Toshifumi Takahashi, and Kae Hashimoto, and Seiji Ogata, and Seiji Tsutsumi, and Keiko Takata, and Tsuyoshi Ohta, and Jun Kawagoe, and Kazuhiro Takahashi, and Hirohisa Kurachi
August 2002, Molecules and cells,
Limei Yin, and Ken-Ichirou Morishige, and Toshifumi Takahashi, and Kae Hashimoto, and Seiji Ogata, and Seiji Tsutsumi, and Keiko Takata, and Tsuyoshi Ohta, and Jun Kawagoe, and Kazuhiro Takahashi, and Hirohisa Kurachi
August 1999, Proceedings of the National Academy of Sciences of the United States of America,
Limei Yin, and Ken-Ichirou Morishige, and Toshifumi Takahashi, and Kae Hashimoto, and Seiji Ogata, and Seiji Tsutsumi, and Keiko Takata, and Tsuyoshi Ohta, and Jun Kawagoe, and Kazuhiro Takahashi, and Hirohisa Kurachi
June 1998, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
Limei Yin, and Ken-Ichirou Morishige, and Toshifumi Takahashi, and Kae Hashimoto, and Seiji Ogata, and Seiji Tsutsumi, and Keiko Takata, and Tsuyoshi Ohta, and Jun Kawagoe, and Kazuhiro Takahashi, and Hirohisa Kurachi
December 1999, International journal of cancer,
Limei Yin, and Ken-Ichirou Morishige, and Toshifumi Takahashi, and Kae Hashimoto, and Seiji Ogata, and Seiji Tsutsumi, and Keiko Takata, and Tsuyoshi Ohta, and Jun Kawagoe, and Kazuhiro Takahashi, and Hirohisa Kurachi
August 2020, Oncology letters,
Limei Yin, and Ken-Ichirou Morishige, and Toshifumi Takahashi, and Kae Hashimoto, and Seiji Ogata, and Seiji Tsutsumi, and Keiko Takata, and Tsuyoshi Ohta, and Jun Kawagoe, and Kazuhiro Takahashi, and Hirohisa Kurachi
December 2014, Oncology reports,
Limei Yin, and Ken-Ichirou Morishige, and Toshifumi Takahashi, and Kae Hashimoto, and Seiji Ogata, and Seiji Tsutsumi, and Keiko Takata, and Tsuyoshi Ohta, and Jun Kawagoe, and Kazuhiro Takahashi, and Hirohisa Kurachi
January 2007, The Journal of international medical research,
Copied contents to your clipboard!